# PDUFA dates September 2027: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2027-09

> 38 FDA catalysts are dated in September 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## All catalysts in September 2027

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Breast Cancer | scheduled | "NCT05629585 (A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05629585)) |
| September 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Cardiovascular Disease | scheduled | "NCT05669755 (REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669755)) |
| September 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Diabetes Mellitus, Type 2 | scheduled | "NCT07415954 (A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-03 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07415954)) |
| September 2027 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT05980949 (Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-07 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05980949)) |
| September 2027 | [PKN605 primary completion](https://sec-api.dev/pdufa/pkn605) | NVS | Atrial Fibrillation | scheduled | "NCT07217067 (A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217067)) |
| September 2027 | [Pcv21 vaccine primary completion](https://sec-api.dev/pdufa/pcv21-vaccine) | SNY | Pneumococcal Immunization | scheduled | "NCT06824181 (Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-10 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824181)) |
| September 2027 | [BMS-986365 primary completion](https://sec-api.dev/pdufa/bms-986365) | BMY | Metastatic Castration-resistant Prostate Cancer | scheduled | "NCT06764485 (A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-12 (ESTIMATED); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06764485)) |
| September 2027 | [Vedolizumab iv primary completion](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Crohn's Disease (CD) | scheduled | "NCT04779320 (A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-13 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04779320)) |
| September 2027 | [TEV-56286 primary completion](https://sec-api.dev/pdufa/tev-56286) | TEVA | Multiple System Atrophy | scheduled | "NCT06568237 (A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-15 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568237)) |
| September 2027 | [Inactivated hepatitis a vaccine (human diploid cell) (1 ml) primary completion](https://sec-api.dev/pdufa/inactivated-hepatitis-a-vaccine-human-diploid-cell) | SVA | Hepatitis A Vaccine | scheduled | "NCT07793227 (Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-15 (ESTIMATED); Lead Sponsor Sinovac Biotech Co., Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07793227)) |
| September 2027 | [Ianalumab s.c. q4w primary completion](https://sec-api.dev/pdufa/ianalumab-s-c-q4w) | NVS | Lupus Nephritis | scheduled | "NCT05126277 (Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05126277)) |
| September 2027 | [Met097 injection primary completion](https://sec-api.dev/pdufa/met097) | PFE | Obesity and Overweight | scheduled | "NCT07311850 (Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-21 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07311850)) |
| September 2027 | [SAR445399 primary completion](https://sec-api.dev/pdufa/sar445399) | SNY | Hidradenitis Suppurativa | scheduled | "NCT07225569 (A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07225569)) |
| September 2027 | [INCA000585 primary completion](https://sec-api.dev/pdufa/inca000585) | INCY | Immune Thrombocytopenia | scheduled | "NCT07104565 (Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-23 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07104565)) |
| September 2027 | [Vedolizumab iv primary completion](https://sec-api.dev/pdufa/vedolizumab-iv) | TAK | Moderately to Severely Active Ulcerative Colitis | scheduled | "NCT03221036 (Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03221036)) |
| September 2027 | [SPINRAZA (nusinersen) primary completion](https://sec-api.dev/pdufa/nusinersen) | BIIB | Spinal Muscular Atrophy | scheduled | "NCT05067790 (A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05067790)) |
| September 2027 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | DLBCL; Diffuse Large B-Cell Lymphoma | scheduled | "NCT05139017 (A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05139017)) |
| September 2027 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small Cell Lung Cancer | scheduled | "NCT07778316 (Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778316)) |
| September 2027 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Advanced Non-Small Cell Lung Cancer | scheduled | "NCT05785767 (A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05785767)) |
| September 2027 | [Bomedemstat primary completion](https://sec-api.dev/pdufa/bomedemstat) | MRK | Essential Thrombocythemia | scheduled | "NCT06456346 (Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06456346)) |
| September 2027 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06585774 (A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585774)) |
| September 2027 | [Ibuzatrelvir primary completion](https://sec-api.dev/pdufa/ibuzatrelvir) | PFE | COVID-19 Infection | scheduled | "NCT07013474 (A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07013474)) |
| September 2027 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Myasthenia Gravis | scheduled | "NCT07217587 (Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217587)) |
| September 2027 | [WEZLANA® (ustekinumab) primary completion](https://sec-api.dev/pdufa/ustekinumab) | JNJ | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic | scheduled | "NCT05092269 (A Long-term Extension Study of Ustekinumab in Pediatric Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-29 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05092269)) |
| September 2027 | [Ibezapolstat primary completion](https://sec-api.dev/pdufa/ibezapolstat) | ACXP | Clostridium Difficile Infection Recurrence | scheduled | "NCT07513285 (ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-29 (ESTIMATED); Lead Sponsor Acurx Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07513285)) |
| September 30, 2027 | [Ruzasvir NDA/BLA submission](https://sec-api.dev/pdufa/ruzasvir) | AVIR |  | scheduled | "If we successfully complete C-FORWARD, our Phase 3 clinical trial, and our HCV development program evaluating BEM/RZR, and we are able to complete and submit the NDA to the FDA on our current projected timeline, we anticipate that this next potential milestone may become due and payable during the three months ending September 30, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1593899/000119312526453807/avir-20260930.htm)) |
| September 2027 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Pancreatic Cancer; Colorectal Cancer (CRC); Breast Cancer | scheduled | "NCT02955940 (An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02955940)) |
| September 2027 | [6-thio-2'-deoxyguanosine primary completion](https://sec-api.dev/pdufa/6-thio-2-deoxyguanosine) | MAIA | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05208944 (THIO Sequenced With Cemiplimab in Advanced NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Maia Biotechnology." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05208944)) |
| September 2027 | [Saruparib primary completion](https://sec-api.dev/pdufa/saruparib) | AZN | Metastatic Castration-Sensitive Prostate Cancer | scheduled | "NCT06120491 (Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06120491)) |
| September 2027 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Motion Sickness | scheduled | "NCT06138613 (Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06138613)) |
| September 2027 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | scheduled | "NCT06241118 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06241118)) |
| September 2027 | [Elx/tez/iva primary completion](https://sec-api.dev/pdufa/elx-tez-iva) | VRTX | Cystic Fibrosis | scheduled | "NCT06460506 (Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06460506)) |
| September 2027 | [Mevrometostat primary completion](https://sec-api.dev/pdufa/mevrometostat) | PFE | Metastatic Castration-Resistant Prostate Cancer | scheduled | "NCT06629779 (A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06629779)) |
| September 2027 | [SAT-3247 primary completion](https://sec-api.dev/pdufa/sat-3247) | MSLE | Duchenne Muscular Dystrophy (DMD) | scheduled | "NCT06867107 (An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Satellos Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06867107)) |
| September 2027 | [LTI-03 primary completion](https://sec-api.dev/pdufa/lti-03) | RNTX | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT06968845 (A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Rein Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06968845)) |
| September 2027 | [Pemvidutide primary completion](https://sec-api.dev/pdufa/pemvidutide) | ALT | Alcohol-associated Liver Disease | scheduled | "NCT07009860 (RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Altimmune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07009860)) |
| September 2027 | [Alpha-1 15% primary completion](https://sec-api.dev/pdufa/alpha-1-15) | GRFS | Alpha 1 Antitrypsin Deficiency | scheduled | "NCT07555483 (A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Grifols Therapeutics LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07555483)) |
| September 2027 | [PTC844 primary completion](https://sec-api.dev/pdufa/ptc844) | PTCT | Rheumatoid Arthritis | scheduled | "NCT07779616 (Study of PTC844 in Participants With Active Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor PTC Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07779616)) |

Other months: https://sec-api.dev/fda-calendar/2027-08 , https://sec-api.dev/fda-calendar/2027-10. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates September 2027: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2027-09

```bibtex
@misc{secapidev_fda_calendar_2027_09_20261116,
  title        = {PDUFA dates September 2027: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2027-09}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2027_09_20261116","title":"PDUFA dates September 2027: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2027-09","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
